What is the official website of Novartis Belux ?

The official website of Novartis Belux is http://www.novartis.be.

What is Novartis Belux's cybersecurity risk score?

Novartis Belux has an AI-generated cybersecurity risk score of 753 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Belux experienced?

According to Rankiteo, Novartis Belux currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Belux been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Belux has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Belux have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Belux is not certified under SOC 2 Type 1.

Does Novartis Belux have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Belux does not hold a SOC 2 Type 2 certification.

Does Novartis Belux comply with GDPR ?

According to Rankiteo, Novartis Belux is not listed as GDPR compliant.

Does Novartis Belux have PCI DSS certification ?

According to Rankiteo, Novartis Belux does not currently maintain PCI DSS compliance.

Does Novartis Belux comply with HIPAA ?

According to Rankiteo, Novartis Belux is not compliant with HIPAA regulations.

Does Novartis Belux have ISO 27001 certification ?

According to Rankiteo,Novartis Belux is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Belux operate in ?

Novartis Belux operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Belux have ?

Novartis Belux employs approximately 146 people worldwide.

Does Novartis Belux own any subsidiaries ?

Novartis Belux presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Belux have ?

Novartis Belux's official LinkedIn profile has approximately 6,839 followers.

What is the NAICS classification code for Novartis Belux ?

Novartis Belux is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Belux have a Crunchbase profile ?

No, Novartis Belux does not have a profile on Crunchbase.

Does Novartis Belux have a LinkedIn profile ?

Yes, Novartis Belux maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-belux.

How many cybersecurity incidents has Novartis Belux experienced ?

As of October 5, 2026, Rankiteo reports that Novartis Belux has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Belux have ?

Novartis Belux has an estimated 5,773 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Belux faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Belux

Boost Score +25 with badge (5 left)

753

/1000

Fair

778

/1000

Fair

Novartis Belux Vendor Cyber Rating & Cyber Score

novartis.be

Add Your Compliance Badge

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. In Belgium, we are proud to be one of the leading life sciences companies with a legacy of more than a century. We focus on core therapeutic areas with high unmet patient needs: cardiovascular, renal and metabolic, oncology, immunology and neuroscience. Our people are our greatest strength: their diversity, energy and creativity are crucial to our success. They make our business by discovering, developing and facilitating access to our medicines. About

Novartis Belux

Novartis Belux CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Belux

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Belux Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Belux

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Belux in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Belux in 2026.

Incident Types Novartis Belux vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Belux in 2026.

Incident History - Novartis Belux (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Belux Subsidiaries

Novartis Belux

Pharmaceutical Manufacturing

Website: http://www.novartis.be

Company Size: 146

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis SverigePharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis IsraelPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Loading…

Novartis Belux Similar Companies

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

SUN PHARMA

sunpharma.com

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Alembic Pharmaceuticals Limited

alembic-india.com

Established in 1907, Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the Macrolides segment of anti-infective drugs in India. Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

Lupin

lupin.com

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

MACLEODS PHARMACEUTICALS LTD.

macleodspharma.com

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.

Novo Nordisk

cb novonordisk.com

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 68,800 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html

Loading…

NEWS

Novartis Belux CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-105222

SUMMARY

The alexpechkarev/google-maps Laravel package through 12.16 disables TLS certificate verification by default because the bundled config sets ssl_verify_peer to FALSE, which is passed to CURLOPT_SSL_VERIFYPEER. On-path attackers can present any certificate to intercept Google Maps web-service requests, steal the API key from the query string, and tamper with responses.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-105221

SUMMARY

The gist RubyGem before 6.1.0 contains an improper certificate validation vulnerability that allows on-path attackers to intercept HTTPS traffic because http_connection in lib/gist.rb sets VERIFY_NONE. Attackers can present any certificate to read or modify GitHub API traffic, stealing OAuth tokens and login credentials to read and modify the victim's gists.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.4)

cvss3

Base Score: 7.4

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:H/I:H/A:N

cvss4

Base Score: 9.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:P/PR:N/UI:N/VC:H/VI:H/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.2

Exploitability

2.2

REFERENCES

CVE-2026-105220

SUMMARY

Twine 2 desktop through 2.12.0 contains a cross-site scripting vulnerability in importStories() that executes markup from imported story files in the editor window. Attackers can craft a story file whose script calls the twineElectron openWithScratchFile IPC bridge to write and open a .bat file, executing code as the user.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.8)

cvss3

Base Score: 7.8

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H

cvss4

Base Score: 8.5

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

5.9

Exploitability

1.8

REFERENCES

CVE-2026-105167

SUMMARY

A vulnerability was determined in kishor-23 food-waste-management-system 411989e3ecb82895e53dca7865f72145f03d7d93/b3a70b2c492dc9904de5be1ad9389bd79b87f82c. The impacted element is an unknown function of the file admin/donate.php. Executing a manipulation of the argument location can lead to sql injection. The attack may be performed from remote. The exploit has been publicly disclosed and may be utilized. This product utilizes a rolling release system for continuous delivery, and as such, version information for affected or updated releases is not disclosed. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

CVE-2026-105166

SUMMARY

A vulnerability was found in kishor-23 food-waste-management-system 411989e3ecb82895e53dca7865f72145f03d7d93/b3a70b2c492dc9904de5be1ad9389bd79b87f82c. The affected element is the function insert of the file fooddonateform.php of the component Food Donation Form. Performing a manipulation of the argument image-choice results in sql injection. The attack is possible to be carried out remotely. The exploit has been made public and could be used. This product adopts a rolling release strategy to maintain continuous delivery. Therefore, version details for affected or updated releases cannot be specified. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-10-04

Updated

Date2026-10-04

RISK INFORMATION (Score: 7.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 7.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.5

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

3.9

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Novartis Belux Vendor Cyber Rating & Cyber Score

Novartis Belux A.I CyberSecurity Scoring

Novartis Belux CyberSecurity News & History

Novartis Belux Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Belux

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Belux vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Belux (X = Date, Y = Severity)

Novartis Belux Subsidiaries

Novartis Belux

Novartis Belux Similar Companies

Intas Pharmaceuticals

SUN PHARMA

Glenmark Pharmaceuticals

PT Kalbe Farma, Tbk

Alembic Pharmaceuticals Limited

Lupin

UCB

MACLEODS PHARMACEUTICALS LTD.

Novo Nordisk

Novartis Belux CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Novartis Belux CyberSecurity News & History

Novartis Belux Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Novartis Belux

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Novartis Belux vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Novartis Belux (X = Date, Y = Severity)

Novartis Belux Subsidiaries

Novartis Belux

Novartis Belux Similar Companies

Intas Pharmaceuticals

SUN PHARMA

Glenmark Pharmaceuticals

PT Kalbe Farma, Tbk

Alembic Pharmaceuticals Limited

Lupin

UCB

MACLEODS PHARMACEUTICALS LTD.

Novo Nordisk

Novartis Belux CyberSecurity News

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo